RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma

Hepatology

Volumn 48, Issue 4, 2008, Pages 1118-1127

  Jeng, Yung Ming ^a   Chang, Cheng Chi ^a   Hu, Fu Chang ^a   Chou, Han Yi E ^a   Kao, Hsin Lien ^a   Wang, Ting Huang ^a   Hsu, Hey Chi ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; INSULIN LIKE GROWTH FACTOR 2 MESSENGER RNA BINDING PROTEIN 3; PROTEIN P53; RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; HIGH MOBILITY GROUP A2 PROTEIN; IMP 3 PROTEIN, HUMAN; IMP-3 PROTEIN, HUMAN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; ENDOTHELIUM; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; SCHOOL CHILD; TISSUE DISTRIBUTION; TUMOR THROMBUS; TUMOR VOLUME; WESTERN BLOTTING; CELL MOTION; CHILD; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CHILD; FEMALE; HMGA2 PROTEIN; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS;

EID: 54449087536     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22459     Document Type: Article

References (41)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S294-S302.
3. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: Progress and prospects. Hepatobiliary Pancreat Dis Int 2002;1:35-41.
4. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002;287:49-54.
5. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19: 1262-1270.
6. Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14: 2729-2733.
7. Havin L, Git A, Elisha Z, Oberman F, Yaniv K, Schwartz SP, et al. RNA-binding protein conserved in both microtubule- and microfilament-based RNA localization. Genes Dev 1998;12:1593-1598.
8. Deshler JO, Highett MI, Abramson T, Schnapp BJ. A highly conserved RNA-binding protein for cytoplasmic mRNA localization in vertebrates. Curr Biol 1998;8:489-496.
9. Prokipcak RD, Herrick DJ, Ross J. Purification and properties of a protein that binds to the C-terminal coding region of human c-myc mRNA. J Biol Chem 1994;269:9261-9269.
10. Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H, et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005;96:100-110.
11. Suzuki T, Maruno M, Wada K, Kagawa N, Fujimoto Y, Hashimoto N, et al. Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol 2004;21:27-34.
12. Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005;65: 439-447.
13. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999;88:95-99.
14. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, et al. KOC (K homology domain containing protein overexpressed in cancer): A novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005;29:188-195.
15. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: A retrospective study. Lancet Oncol 2006;7:556-564.
16. Schwartz SP, Aisenthal L, Elisha Z, Oberman F, Yisraeli JK. A 69-kDa RNA-binding protein from Xenopus oocytes recognizes a common motif in two vegetally localized maternal mRNAs. Proc Natl Acad Sci U S A 1992;89:11895-11899.
17. Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006;25:1456-1468.
18. Zhang J, Chan EK. Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. Autoimmun Rev 2002;1:146-153.
19. Edmonson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 among 489,000 necropsies. Cancer (Phila) 1954;7:462-503.
20. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997:98-126.
21. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res 1993;53:4691-4694.
22. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-770.
23. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of anti-bemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973;52:2757-2764.
24. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley & Sons, 2000.
25. Hosmer DW, Lemeshow S. Applied survival analysis: Regression modeling of time to event data. New York: John Wiley & Sons; 1999.
26. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549-558.
27. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, et al. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: Association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, β-catenin mutation, and favorable prognosis. Clin Cancer Res 2005;11:2568-2575.
28. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065-2071.
29. Peng SY, Ou YH, Chen WJ, Li HY, Liu SH, Pan HW, et al. Aberrant expressions of annexin A10 short isoform, osteopontin and α-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 2005;26:1053-1061.
30. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 2007;43:736-744.
31. Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, et al. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 2007;13:5368-5376.
32. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
33. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006;66:4279-4284.
34. Nutt CL, Matthews RT, Hockfield S. Glial tumor invasion: A role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist 2001;7: 113-122.
35. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA. Growth factor-induced cell motility in tumor invasion. Acta Oncol 2002;41:124-130.
36. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008;14: 2334-2340.
37. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, et al. The oncofetal protein IMP3: A novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304-315.
38. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: An immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 2007;20:242-247.
39. Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant'Agnese PA, Wang HL, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 2007;38:1178-1183.
40. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 200;21:1025-1030.
41. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006;13:1185-1191.